product oper focu drive valu
backlog rose record reflect
organ revenu growth support solid visibl slightli rais guidanc
consist sound end market aero process engin materi analyt
medic span high end applic instrument portfolio well
focu mix consist price abil emg margin rose bp y-o-
solid read core new acquisit contribut larg
lap extend emg om expans three straight quarter overal margin
flat y-o-i strong bp exclud dilut first year
acquisit ad growth steadi organ compound continu
compar organ organ
adjust ep beat in-lin
guidanc sale core acq fx vs
estim op rose vs estim guidanc ep revis
vs prior consensu y-o-i sale still
high-singl digit core
sale grew y-o-i core acq fx om
bp y-o-i bp organ match estim emg sale
grew y-o-i core acq fx om expand bp y-
o-i vs bp estim
organ order rose includ emg emg order
rose estim acquisit growth recent
deal includ balanc end
net debt/ebitda activ acquisit pipelin
china organ revenu msd includ softer macro tough
compar coupl project-bas revenu sourc push march
acceler nice weak februari full year like correl total
rais
rais pt target consist current
multipl support sustain compound model highli
probabl acquir prospect solid return
year price histori
analyst certif import disclosur see disclosur
expect posit investor sentiment given
sustain compound model highli probabl
acquir prospect solid return high /ni convers
strong backlog underwrit outlook attent focus
solid order trend deal flow remain solid robust
recent deal play well oper improv capac
strong convers capit alloc prospect
acceler replenish record backlog
success mitig uncertain tariff headwind
inabl execut difficult organ comp
inabl execut integr acquisit expect
pt base consist current multipl support sustain compound model
highli probabl acquir prospect solid return pt impli potenti upsid includ dividend yield
risk includ weaker global growth includ us weak aerospac oil/gas/chem market inabl
complete/integr acquisit given relianc acquisit supplement top line inabl pass along higher raw materi cost
price aggress consensu ep estim time could hinder stock price perform
exhibit segment result varianc oppenheim estim
compani report oppenheim co inc estim
report adjust ep vs year ago beat in-lin estim
guidanc revenu increas organ acquisit fx
vs estim order increas y-o-i
segment oper margin flat y-o-i vs estim consolid basi
oper margin flat y-o-i core bp y-o-i edg estim exclud
dilut effect acquisit core margin expand bp
flow/liquid guid fcf/ni end net debt/ebitda
cash hand
guidanc manag revis ep guidanc vs prior
consensu y-o-i sale outlook still high-singl digit organ sale still
expect full-year tax rate capital-expenditure depreci amort
guid ep vs prior consensu sale high-singl
compani report oppenheim co inc estim
electron instrument revenu increas y-o-i organ acquisit
fx vs estim aerospac grew high-singl digit y-o-i high-singl digit organ
process increas mid-teen msd organ power industri grew mid-singl digit flat organ
oper margin contract bp y-o-i core bp y-o-i match estim
includ bp dilut first year affect acquisit organ order rose
electromechan revenu grew y-o-i organ acquisit fx vs
estim engin solut organ sale increas mid-singl digit
oper margin expand bp y-o-i beat estim organ order rose
annual sale profit segment
compani report oppenheim co inc
quarterli sale profit segment
compani report oppenheim co inc
analysi oper
segment revenu
total segment revenu
segment profit
total segment profit
compani report oppenheim co inc
year end decemb million
good sold
oper profit g/w charg
compani report oppenheim co inc
sale
oper profit g/w charg
compani report oppenheim co inc
year end decemb million
equival
intang invest asset
short-term borrow current portion ltd
average day inventori day hand
compani report oppenheim co inc
consolid statement flow
year end decemb million
inventori current asset
payabl accrual incom tax
net chang work capit
addit pp
proce sale asset discontinu op
purchas busi net cash
net chang short-term borrow
reduct long-term borrow
repurchas common stock
excess tax benefit share-bas payment
proce employe stock option
increas dec
equival -b
equival -e
compani report oppenheim co inc
